Related Experiment Video
Updated: Jun 25, 2026
Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives
Published on: September 16, 2021
Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome
Akos Várnagy1, József Bódis, Zoltán Mánfai
1Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Pécs, H-7624 Pécs, Hungary. akos.varnagy@aok.pte.hu
Objective:
To evaluate the effect of low-dose aspirin therapy on ovarian hyperstimulation syndrome (OHSS) in an unselected group of patients undergoing in vitro fertilization (IVF).
Design:
Randomized clinical trial.
Setting:
Division of Reproductive Medicine at the Department of Obstetrics and Gynecology, University of Pécs, Faculty of Medicine, Pécs, Hungary.
Patient(S):
Patients who underwent IVF between 2000 and 2006.
Intervention(S):
Initiation of 3154 IVF cycles, for which gonadotropin-releasing hormone agonist was used in 2425 cycles; 1503 cycles randomly selected for low-dose aspirin treatment starting from the first day of controlled ovarian hyperstimulation compared with no treatment in the remaining 922 cycles.
Main Outcome Measure(S):
The incidence of severe or critical OHSS and the rate of clinical pregnancy.
Result(S):
During this time period, 45 cases of severe OHSS were detected. Only two of the OHSS patients had received aspirin previously.
Conclusion(S):
Based on our preliminary results, introduction of low-dose aspirin therapy during ovulation induction for the prevention of OHSS in high-risk patients should be considered.
Related Concept Videos
01:30Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
02:07Oogenesis
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists